Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
In one study, 732 patients with primary progressive MS were randomized on a 2:1 ratio to receive either ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, or a placebo.
The proportion of patients with 12-week confirmed disability progression was 39.3 per cent with the placebo versus 32.9 per cent with ocrelizumab. After 24 weeks, the proportion with confirmed disability progression was 35.7 per cent with placebo versus 29.6 per cent with ocrelizumab. By week 120, timed 25-foot walk worsened by 55.1 per cent for placebo versus 38.9 per cent for ocrelizumab. Patients given ocrelizumab were also found to have fewer new brain lesions and less brain volume loss than those given the placebo.
Researchers also tested ocrelizumab in two separate studies of patients with relapsing remitting MS, one a group of 821 and the other 835. In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. Compared to the placebo, relapse rates in patients given ocrelizumab were 46-per-cent lower in one study and 47-per-cent lower in the other. Ocrelizumab was found to reduce the risk of disability progression after 12 weeks and 24 weeks, and reduced the number of new brain lesions.
The study noted that infusion-related reactions occurred in 34.3 per cent of ocrelizumab-treated patients. Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. Further observation is required to determine the long-term safety of ocrelizumab.
“The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses,” says Bar-Or. “While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field.”
These studies, funded by Roche, were published in the New England Journal of Medicine on Dec. 21, 2016.
MS in Canada
Canada has one of the world’s highest rates of MS – about 1,100 new cases each year. Some 50,000 Canadians have MS, and more than one-in-five patients are in Quebec. MS is one of the most common neurological diseases among young Canadians. Children as young as two can develop the disease. It typically strikes people in their prime years, between 15 and 40. Women are twice as likely as men to contract MS.
Learn more: Breakthrough in MS treatment
Receive an email update when we add a new MULTIPLE SCLEROSIS article.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Celgene and the Multiple Sclerosis Association of America Team Up to Launch MS MindShift for Awareness of Multiple Sclerosis and Brain Health on May 21, 2019 at 5:01 am
Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) today announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that ... […]
- Global agreement reached on standards for clinical trials in children with multiple sclerosis on May 20, 2019 at 11:48 pm
"Thankfully, the number of pediatric MS cases is low compared to adult cases—but these are children, facing a chronic illness and we need to do everything we can to help them," said lead author ... […]
- United States : Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis on May 20, 2019 at 1:16 pm
May 20, 2019 (Euclid Infotech Ltd via COMTEX) -- Celgene Corporation announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE Part B trial showing that ozanimod reduced cortical ... […]
- Corrona Expands Its Real-World Evidence Registry Collaboration for Patients with Multiple Sclerosis on May 20, 2019 at 6:00 am
WALTHAM, Mass., May 20, 2019 /PRNewswire/ -- Corrona, LLC is pleased to announce a key milestone for the Corrona [®] Multiple Sclerosis (MS) Registry, a real-world US-based registry developed as a ... […]
- A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis on May 20, 2019 at 2:09 am
Genome-wide association studies (GWAS) have identified more than 50,000 unique associations with common human traits. While this represents a substantial step forward, establishing the biology ... […]
- Clinical Challenges: Testing Your Knowledge of Multiple Sclerosis on May 17, 2019 at 8:01 am
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. © 2019 MedPage Today, LLC ... […]
- Oh, How I Hate Multiple Sclerosis on May 17, 2019 at 7:48 am
I’m oft to say that living with an incurable disease is better than the alternative. That’s to say, if it’s incurable, “living” with it is better than not living. It’s my way of getting on with life ... […]
- Warren Man To Bike 25 Miles For Multiple Sclerosis, Raise $10,000 on May 17, 2019 at 7:03 am
Ed Ronan of Warren will be biking to raise funds and awareness for Multiple Sclerosis on Saturday. (Image provided) Ed Ronan of Warren will be biking to raise funds and awareness for Multiple ... […]
- Clinical Challenges: PML in Multiple Sclerosis on May 16, 2019 at 7:53 am
For the last 15 years, progressive multifocal leukoencephalopathy (PML) has attracted a lot of attention from the multiple sclerosis (MS) community. As Joseph Berger, MD, chief of the multiple ... […]
via Bing News